A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY South Korean MOHW Officials Announce Roadmap for South Korea to Become No. 7 Worldwide in New Drug Development by 2020
July 19, 2013
-
BUSINESS Pfizer Paid 23.9 Billion Yen to Physicians, Medical Institutions in FY2012; 1st Disclosure under JPMA Guidelines
July 18, 2013
-
ACADEMIA University’s Seriousness to Unravel Diovan Saga Called into Question
July 17, 2013
-
REGULATORY 2nd Committee on Drugs to Discuss Approval for Asthma Treatment Flutiform on July 26
July 17, 2013
-
REGULATORY MHLW, US FDA to Exchange Information with a View to Standardizing Review Guidelines for Regenerative Medicines
July 17, 2013
-
REGULATORY Health Ministry to Set Up Committee on Diovan Studies, Compile Preventive Measures for Clinical Data Manipulation
July 16, 2013
-
REGULATORY MHLW Presses Kyoto Prefectural University of Medicine to Carry on Diovan Probe
July 16, 2013
-
ACADEMIA “Data Manipulated” in KYOTO Heart Study: Univ. Probe
July 12, 2013
-
ORGANIZATION JPWA Sets Up New Committee on Consumption Tax, NHI Drug Pricing Issues
July 12, 2013
-
BUSINESS Drug Makers to Disclose Payment Information This Summer Based on Transparency Guidelines
July 11, 2013
-
BUSINESS Blood Derivative Titan CSL Set to Beef Up Japan Biz with New Products
July 10, 2013
-
REGULATORY TPP Member States to Brief Japan on Drug Pricing, Intellectual Property on July 25
July 9, 2013
-
ORGANIZATION JSGM Officially Announces Unified Brand Name Plan for Generic Combination Drugs; 1st Single Name to Be Given to Preminent
July 8, 2013
-
ORGANIZATION JSGM Working to Build Consensus on Unified Brand Names for Generic Combination Drugs
July 5, 2013
-
ACADEMIA “No Data Manipulation” in VART Study of Diovan: Interim Report of Japanese Society of Hypertension
July 4, 2013
-
REGULATORY Notification Calls for Simultaneous Filing of Applications for Companion Diagnostics and Drugs
July 3, 2013
-
BUSINESS Japanese Society of Chemotherapy Joins Hands with Pharmas, Govt to Spur New Antibiotic Development
July 2, 2013
-
ORGANIZATION JMA Sets Up Pharmaceutical Affairs Section
July 1, 2013
-
BUSINESS Bayer Yakuhin to Shift Resources to Innovative New Drugs: President Brunn
June 28, 2013
-
ACADEMIA NHO Attains 30% Volume-Based Generic Target in FY2012
June 28, 2013
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…